Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus

被引:7
|
作者
Bayomy, Omar [1 ]
Rao, Ajay D. [1 ,2 ,3 ,4 ]
Garg, Rajesh [1 ,2 ]
Vaidya, Anand [1 ,2 ]
Kotin, Alyssa R. [2 ]
Reiber, Beata [5 ]
Nijmeijer, Stephanie [5 ]
Di Carli, Marcelo F. [1 ,5 ,6 ]
Jerosch-Herold, Michael [1 ,5 ]
Kwong, Raymond Y. [1 ,6 ]
Adler, Gail K. [1 ,2 ]
机构
[1] Harvard Med Sch, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave, Boston, MA 02115 USA
[3] Lewis Katz Sch Med, Sect Endocrinol Diabet & Metab, Philadelphia, PA USA
[4] Lewis Katz Sch Med, Ctr Metab Dis Res, Philadelphia, PA USA
[5] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
type; 2; diabetes; plasminogen activator inhibitor-1; pericardial fat; adipose tissue; EPICARDIAL ADIPOSE-TISSUE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK-FACTORS; PAI-1; ASSOCIATION; HEART; DYSFUNCTION; EXPRESSION; PREVENTION;
D O I
10.1089/met.2017.0031
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Plasminogen activator inhibitor-1 (PAI-1) is implicated in the pathophysiology of cardiovascular disease (CVD) and increased in individuals with type 2 diabetes mellitus (T2DM). Adipose tissue produces PAI-1, and pericardial fat is a CVD risk factor. We sought to determine the relationship between PAI-1 and pericardial fat in males and females with well-controlled T2DM. Methods: The study population consisted of 32 males and 19 females, aged 35-70 years with T2DM, without clinical evidence of CVD or other active medical problems except for hypertension. Subjects were studied under good cardiometabolic control. Study procedures included fasting blood work and cardiovascular imaging. Cardiac magnetic resonance imaging of the heart was used to identify and quantify pericardial fat from the bifurcation of the pulmonary trunk to the last slice containing cardiac tissue. Results: PAI-1 was positively correlated with pericardial fat (beta = 0.72, r = 0.72, P < 0.001) as well as with homeostatic model assessment of insulin resistance (r = 0.31, P = 0.03) and serum triglycerides (r = 0.27, P = 0.05). In a multivariable regression model, controlling for insulin sensitivity, triglycerides, and body mass index, pericardial fat was independently associated with PAI-1 (beta = 0.80, P < 0.001). Conclusions: PAI-1 is positively associated with pericardial fat in individuals with T2DM.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 50 条
  • [41] Plasminogen activator inhibitor-1 and Restenosis
    Garg, Nadish
    Fay, William P.
    CURRENT DRUG TARGETS, 2007, 8 (09) : 1003 - 1006
  • [42] Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1
    Lin, Zhonghui
    Jiang, Longguang
    Yuan, Cai
    Jensen, Jan K.
    Zhang, Xu
    Luo, Zhipu
    Furie, Barbara C.
    Furie, Bruce
    Andreasen, Peter A.
    Huang, Mingdong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (09) : 7027 - 7032
  • [43] Expression of urokinase type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer
    Kawasaki, K
    Hayashi, Y
    Wang, Y
    Suzuki, S
    Morita, Y
    Nakamura, T
    Narita, K
    Doe, W
    Itoh, H
    Kuroda, Y
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (09) : 936 - 944
  • [44] There is no covalent interaction between plasminogen activator inhibitor-1 with urokinase-type plasminogen activator
    Wang, Q
    Shaltiel, S
    MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 513A - 513A
  • [45] Impact of scaling and root planing on salivary and serum plasminogen activator inhibitor-1 expression in patients with periodontitis with and without type 2 diabetes mellitus
    Guru, Sanjeela R.
    Aghanashini, Suchetha
    JOURNAL OF PERIODONTOLOGY, 2023, 94 (01) : 20 - 30
  • [46] Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients
    Lindgren, A
    Lindoff, C
    Norrving, B
    Astedt, B
    Johansson, BB
    STROKE, 1996, 27 (06) : 1066 - 1071
  • [47] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
    Zhou, L
    Hayashi, Y
    Itoh, T
    Wang, WP
    Rui, JA
    Itoh, H
    PATHOLOGY INTERNATIONAL, 2000, 50 (05) : 392 - 397
  • [48] The role of the platelet pool of Plasminogen Activator Inhibitor-1 in well-controlled type 2 diabetes patients
    Mossberg, Karin
    Olausson, Josefin
    Fryk, Emanuel
    Jern, Sverker
    Jansson, Per-Anders
    Brogren, Helen
    PLOS ONE, 2022, 17 (08):
  • [49] The relationship between plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis
    James Yarmolinsky
    Natália Bordin Barbieri
    Tobias Weinmann
    Bruce B Duncan
    Maria Inês Schmidt
    Diabetology & Metabolic Syndrome, 7 (Suppl 1):
  • [50] Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies
    Yarmolinsky, James
    Barbieri, Natalia Bordin
    Weinmann, Tobias
    Ziegelmann, Patricia K.
    Duncan, Bruce B.
    Schmidt, Maria Ines
    SCIENTIFIC REPORTS, 2016, 6